Skip to main content
. Author manuscript; available in PMC: 2010 Aug 9.
Published in final edited form as: Biochem Pharmacol. 2008 Oct 14;77(4):566–576. doi: 10.1016/j.bcp.2008.09.039

Figure 5. Perinatal and adult exposure to AHR agonists differentially affects the risk of prostate disease.

Figure 5

Sustained activation of AHR in the UGS by TCDD during fetal prostate development increases the risk of prostate cancer in adulthood, whereas activation of AHR signaling in the prostate during adulthood by TCDD, other full AHR agonists, and selective AHR modulators (SARHMs) are protective against prostate cancer and/or benign prostate hyperplasia.